AstraZeneca fulfills contract with Panama after delivery of 163,200 new doses
According to the Expanded Program on Immunization (EPI) Panama has received a total of 1,212,000 doses of the AstraZeneca vaccine.
Panama received at dawn this Sunday 163,200 new doses of the vaccine against covid-19 developed by the pharmaceutical AstraZeneca.
With the arrival of this eighth shipment, AstraZeneca fulfills the delivery of one million doses agreed with Panama.
Foreign Minister Erika Mouynes reported that Panama is the first country in Latin America to receive all the doses agreed bilaterally with this pharmaceutical company.
According to the Expanded Program on Immunization (PAI), Panama has received 1,212,000 doses of the AstraZeneca vaccine between the Covax mechanism and the bilateral route.
In the country, the AstraZeneca vaccine is applied to men and women over 30 years of age on a voluntary basis.
According to the latest EPI report in Panama, 5,175,291 vaccines have been applied nationally, including first and second doses of Pfizer and AstraZeneca.
From the pharmaceutical house Pfizer, 4,435,065 vaccines have been applied, while 740,226 doses have been placed from AstraZeneca.
With the arrival of this eighth shipment, AstraZeneca fulfills the delivery of one million doses agreed with Panama.
Foreign Minister Erika Mouynes reported that Panama is the first country in Latin America to receive all the doses agreed bilaterally with this pharmaceutical company.
According to the Expanded Program on Immunization (PAI), Panama has received 1,212,000 doses of the AstraZeneca vaccine between the Covax mechanism and the bilateral route.
In the country, the AstraZeneca vaccine is applied to men and women over 30 years of age on a voluntary basis.
According to the latest EPI report in Panama, 5,175,291 vaccines have been applied nationally, including first and second doses of Pfizer and AstraZeneca.
From the pharmaceutical house Pfizer, 4,435,065 vaccines have been applied, while 740,226 doses have been placed from AstraZeneca.
